Posts Tagged ‘Blood pressure’

Page 1 of 3123

Tirofiban effectively prevents strokes in high risk patients

Tirofiban effectively prevents strokes in high risk patients

Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).

Work by a new research group, led by Professor Donald Singer, Professor of Therapeutics at Warwick Medical School and Professor Chris Imray from UHCW, has now been published in US journal Stroke.

The group is using ultrasound scanning to look at patients with carotid artery disease, one of the major causes of stroke. Clots can form on diseased carotid arteries in the neck. Small parts of these clots can released to form microemboli, which can travel to block key brain arteries and lead to weakness, disturbed speech, loss of vision and other serious stroke syndromes. Standard anti-platelet drugs such as aspirin may not prevent the formation of harmful microemboli.

The scanning process can be used to find patients at very high risk of stroke because microemboli have formed despite prior anti-platelet drugs. Using scanning, the team has found that tirofiban, another anti-platelet drug designed to inhibit the formation of blood clots, can suppress microemboli where previous treatment such as aspirin has been ineffective. In their study, tirofiban was more effective than other ‘rescue’ treatment.

Professor Singer said: “These findings show that the choice of rescue medicine is very important when carotid patients develop microemboli despite previous treatment with powerful anti-platelet drugs such as aspirin. We now need to go on to further studies of anti-microemboli rescue treatments, to aim for the right balance between protection and risk for our patients.”

Professor Imray said: “These findings show the importance of ultrasound testing for micro-emboli in carotid disease patients. These biomarkers of high stroke risk cannot be predicted just from assessing the severity of risk factors such as smoking history, cholesterol and blood pressure.”

Source : http://www.news-medical.net/news/20121122/Tirofiban-effectively-prevents-strokes-in-high-risk-patients.aspx

Full story

Tirofiban effectively prevents strokes in high risk patients

Tirofiban effectively prevents strokes in high risk patients

Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).

Work by a new research group, led by Professor Donald Singer, Professor of Therapeutics at Warwick Medical School and Professor Chris Imray from UHCW, has now been published in US journal Stroke.

The group is using ultrasound scanning to look at patients with carotid artery disease, one of the major causes of stroke. Clots can form on diseased carotid arteries in the neck. Small parts of these clots can released to form microemboli, which can travel to block key brain arteries and lead to weakness, disturbed speech, loss of vision and other serious stroke syndromes. Standard anti-platelet drugs such as aspirin may not prevent the formation of harmful microemboli.

The scanning process can be used to find patients at very high risk of stroke because microemboli have formed despite prior anti-platelet drugs. Using scanning, the team has found that tirofiban, another anti-platelet drug designed to inhibit the formation of blood clots, can suppress microemboli where previous treatment such as aspirin has been ineffective. In their study, tirofiban was more effective than other ‘rescue’ treatment.

Professor Singer said: “These findings show that the choice of rescue medicine is very important when carotid patients develop microemboli despite previous treatment with powerful anti-platelet drugs such as aspirin. We now need to go on to further studies of anti-microemboli rescue treatments, to aim for the right balance between protection and risk for our patients.”

Professor Imray said: “These findings show the importance of ultrasound testing for micro-emboli in carotid disease patients. These biomarkers of high stroke risk cannot be predicted just from assessing the severity of risk factors such as smoking history, cholesterol and blood pressure.”

Source : http://www.news-medical.net/news/20121122/Tirofiban-effectively-prevents-strokes-in-high-risk-patients.aspx

Full story

euHeart Computer Modeling Project Aims to Build a Virtual Heart

euHeart Computer Modeling Project Aims to Build a Virtual Heart

euHeart Computer Modeling Project Aims to Build a Virtual Heart

Every year, 18,000 psychiatric client separations take place in Dutch mental healthcare facilities. Philips and GGzE are investigating an alternative for separation and hope to introduce a new care concept, which is embedded in a permanent research project. Today, Philips and GGzE jointly open the newly built High Care Unit at the GGzE premises in Eindhoven. In this unit an Ambient Experience for Mental Healthcare pilot concept is installed. This care concept is based on the Philips Ambient Experience solution and uses a unique combination of dynamic light, sound and projection. It is intended to reduce the clients’ stress and anxiety by supporting and involving them in their own care. With this new care concept Philips and GGzE aspire to reduce the number of psychiatric client separations. GGzE is the world’s first institution to install this innovative prototype in its High Care Unit.

Placing a client in separation is a last resort for both the client and the caregiver. Research indicates that, on average, a client placed in separation spends twice as long in a mental healthcare institution. This can lead to traumatization of the client, demotivation of the caregiver due to feelings of powerlessness, and increasing healthcare costs for the institution and the government.

Philips Ambient Experience as starting point

When Philips and GGzE started their research into a new concept –intended to increase the well-being of both psychiatric clients as well as staff– where better to start than with the tried and tested Philips Ambient Experience solution? This solution integrates architecture, design and enabling technologies such as dynamic lighting, video projections and sound. It allows patients to personalize their environment and surround themselves in a relaxing atmosphere before they will undergo, for example, an MRI scan. Today, more than 400 hospitals globally have installed the Philips Ambient Experience in a range of clinical environments.

Exploring new workflows to reduce stress and anxiety

GGzE and Philips took the Philips Ambient Experience’s key features from the hospital environment to a mental healthcare environment, and applied this when investigating the entire workflow. From the very start when a client that is about to escalate enters the High Care Unit, to the point when the client has returned to a calmer state and can leave the High Care Unit. From the intake room, through the hallway, to the support room; everything is designed with the intention to provide the client control and distraction and give the client the opportunity to maintain communication with the outside world. Our hope is that this may lead to a decrease of stress and discomfort and ultimately give the client a safe and secure feeling.

Involving clients in their own care

The client can select an Ambient Experience theme which he or she finds comforting, meaning the entire high care unit transforms in this theme. Dynamic cove lighting beckons the client gently towards the support room, so that the need for coaxing by the caregiver may become redundant. The support room’s main asset is a large interactive wall. Its multiple-option screen can display nature scenes that have the aim to reduce stress levels. And when the client is more responsive to stimulus, he or she can engage in activities that may support recovery and help in analysis and treatment.

Future plans for this research concept

This new care concept is a first in the world pilot installment. “At our new high care facility, we want to provide outstanding care in a healing environment, in line with our Planetree-approach*,” says Marie-Louise Vossen, GGzE Board Member. “We would like clients in a crisis situation to experience how they can rapidly regain control, through dynamic light, sound and image.”

“A great deal of research still needs to be done; we will investigate if separation rooms as we know them today ideally can be replaced by these kind of Ambient Experience support rooms in the near future,” concludes Werner Satter, General Manager Philips Ambient Experience. “We are continuing our research into this newly-entered area of health and well-being and aspire to create optimal treatment solutions, reducing the number of psychiatric patient separations and increasing the client’s and the staff’s well-being.”

*Planetree is an integrated approach which aims to provide more personal, human and patient-centered healthcare.

Philips Electronics is leading a new EU project to design a virtual heart that can be used as a model for research on the organ.

The euHeart consortium aims to develop advanced computer models of the human heart that can be personalized to patient-specific conditions using clinical data from various sources, such as CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans, measurements of blood flow and blood pressure in the coronary arteries (which feed the heart muscles) and ECGs (Electrocardiograms).

These computer models will integrate the behavior of the heart and the aorta at molecular, cellular, tissue and organ-level. They will also incorporate clinical knowledge about how cardiovascular disease disturbs the correct functioning of the heart at these levels. As a result, it may be possible to develop simulation tools that doctors can use to predict the outcome of different types of therapy, and because the models will be personalized to individual patients, the therapy could be equally personalized.

“euHeart is a very exciting project that will bring together the latest advances in modeling and computing to improve the care of patients with heart disease,” says Professor Reza Razavi, the Project’s Clinical Coordinator who is also Professor of Paediatric Cardiovascular Science and Head of the Division of Imaging Sciences at King’s College London (London, United Kingdom). “It may ultimately allow us to select and optimize the best treatment for individual patients.”

As an example, one way of treating heart rhythm disorders is a minimally invasive procedure known as radio-frequency ablation. During this procedure, a catheter is inserted into the patient’s heart and the tissue responsible for propagating abnormal electrical signals through the heart muscle is destroyed using heat from a radio-frequency field generated at the tip of the catheter. At the moment, doctors have to rely on their experience to decide which areas of tissue to destroy – a task that is complicated by the fact that the electrical activity in every patient’s heart is subtly different. With the aid of a computerized model that reflects the patient’s unique heart structure and function, doctors may be able to test the results of destroying different areas of tissue before they have to operate on the patient.

Source : http://www.newscenter.philips.com/main/standard/news/press/2012/20121003-philips-and-ggze-aim-to-reduce-psychiatric-client-separations.wpd#.UK7YgavVYQs

Full story

Tirofiban effectively prevents strokes in high risk patients

Tirofiban effectively prevents strokes in high risk patients

Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).

Work by a new research group, led by Professor Donald Singer, Professor of Therapeutics at Warwick Medical School and Professor Chris Imray from UHCW, has now been published in US journal Stroke.

The group is using ultrasound scanning to look at patients with carotid artery disease, one of the major causes of stroke. Clots can form on diseased carotid arteries in the neck. Small parts of these clots can released to form microemboli, which can travel to block key brain arteries and lead to weakness, disturbed speech, loss of vision and other serious stroke syndromes. Standard anti-platelet drugs such as aspirin may not prevent the formation of harmful microemboli.

The scanning process can be used to find patients at very high risk of stroke because microemboli have formed despite prior anti-platelet drugs. Using scanning, the team has found that tirofiban, another anti-platelet drug designed to inhibit the formation of blood clots, can suppress microemboli where previous treatment such as aspirin has been ineffective. In their study, tirofiban was more effective than other ‘rescue’ treatment.

Professor Singer said: “These findings show that the choice of rescue medicine is very important when carotid patients develop microemboli despite previous treatment with powerful anti-platelet drugs such as aspirin. We now need to go on to further studies of anti-microemboli rescue treatments, to aim for the right balance between protection and risk for our patients.”

Professor Imray said: “These findings show the importance of ultrasound testing for micro-emboli in carotid disease patients. These biomarkers of high stroke risk cannot be predicted just from assessing the severity of risk factors such as smoking history, cholesterol and blood pressure.”

Source : http://www.news-medical.net/news/20121122/Tirofiban-effectively-prevents-strokes-in-high-risk-patients.aspx

Full story

Ardian’s Hypertension Treatment Outperforms Traditional Medical Treatment in Clinical Trial

Ardian’s Hypertension Treatment Outperforms Traditional Medical Treatment in Clinical Trial

Ardian’s Hypertension Treatment Outperforms Traditional Medical Treatment in Clinical Trial

Background

Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension.

Methods

In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov, number NCT00888433.

Findings

106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p

Interpretation

Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients.

CHICAGO–(BUSINESS WIRE)–Late-breaking data presented today at the American Heart Association Scientific Sessions 2010 and simultaneously published in The Lancet demonstrated that the landmark Symplicity HTN-2 trial evaluating Ardian’s Symplicity® Catheter System™ met its primary endpoint.

“The impressive results of this study show that Ardian’s Symplicity System has the potential to become a truly revolutionary treatment”

The study showed that, after six months, patients treated with Ardian’s device experienced an average drop in blood pressure of 32/12 mmHg compared to an increase in blood pressure of 1/0 mmHg in the control group of patients treated with medical therapy alone (p<0.0001).

Research has shown that each incremental 20/10 mmHg increase of blood pressure above normal levels is associated with a doubling of cardiovascular mortality over a 10 year period1 and that reducing systolic blood pressure by as little as 5 mmHg can reduce the risk of stroke by almost 30 percent.2

“The impressive results of this study show that Ardian’s Symplicity System has the potential to become a truly revolutionary treatment,” said Murray Esler, M.D., Ph.D., principal investigator of the trial and associate director of the Baker IDI Heart and Diabetes Institute of Melbourne, Australia. “Combined with findings from the earlier Symplicity HTN-1 study, which demonstrated the safety and durability of the therapy out to two years, these results fuel our enthusiasm for the potential of this treatment to significantly impact the standard of care for the large number of patients suffering from this disease.”

The Symplicity HTN-2 trial was an international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension. One hundred-six patients were enrolled from 24 investigational sites. At baseline the randomized treatment and control patients had similar high blood pressures: 178/97 mmHg and 178/98 mmHg, respectively, despite both receiving an average daily regimen of five antihypertensive medications. After six months, the average blood pressure of the renal denervation group was reduced to 146/85 mmHg, compared to an average blood pressure of 179/98 mmHg for the control group.

The study also found that the therapy was safe, with no serious device or procedure-related events, no cardiovascular complications and no kidney-related complications.

“Hypertension is often described as a ‘silent killer’ as it frequently has no symptoms yet significantly increases a patient’s risk of heart attack, stroke or death,” said Andrew Cleeland, president and CEO of Ardian, Inc. “Positive data from the Symplicity HTN-2 trial reinforces our belief that this treatment has the potential to significantly improve the quality of life for the millions of people around the world with uncontrolled hypertension. We look forward to beginning a U.S. pivotal study of the device to gather data needed to bring this promising therapy to patients and physicians in the United States.”

About the Symplicity® Catheter System™

The Symplicity Catheter System is used to perform a procedure termed renal denervation (RDN). In a straight-forward endovascular procedure, similar to an angioplasty, the physician inserts the small, flexible Symplicity Catheter into the femoral artery in the upper thigh and threads it into the renal artery. Once in place within the renal artery, the device delivers low-power RF energy to deactivate the surrounding renal sympathetic nerves. This, in turn, reduces hyper-activation of the sympathetic nervous system, which is often the cause of chronic hypertension. The one-time procedure aims to permanently reduce blood pressure. RDN may also allow patients to reduce or eliminate the need for lifelong antihypertensive medications.

In addition to hypertension, the therapy may hold promise for treating heart failure, diabetes and chronic kidney disease, conditions also characterized by elevated sympathetic nerve activity. The Symplicity Catheter System has received CE Mark approval in the European Union and is investigational in the United States. Visit http://www.ardian.com/patients/symplicity.shtml to view an animation of the device and the procedure.

About Hypertension

Though it has no symptoms, hypertension (high blood pressure) is the number one risk factor for premature death worldwide, affecting about one in three adults.3 Nearly half of Europeans suffer from hypertension4 and in the United States, approximately 75 million people are affected, only two-thirds of whom are treated.5 Of those receiving treatment, approximately half are not achieving target blood pressure levels. The medications often prescribed for hypertension must be taken daily for the duration of a patient’s life, can be costly, and often result in side effects that can negatively impact quality of life. Globally, the estimated annual healthcare expenditure directly related to hypertension is approximately $500 billion.6

About Ardian

Privately held Ardian Inc., based in Mountain View, Calif., develops catheter-based therapies to treat hypertension and related conditions. Ardian is the eighth company created by The Foundry, a leading medical device incubator based in Menlo Park, Calif. Ardian’s investors include Morgenthaler Ventures, Advanced Technology Ventures, Split Rock Partners, Medtronic and Emergent Medical Partners. For more information, please visit www.ardian.com.

Mountain View, CA based Ardian Inc. has announced the results of a six month study which evaluated the company’s Symplicity Catheter System for treatment of chronic drug resistant hypertension. The study compared the outcomes of patients taking three or more antihypertensive drugs to those treated with the Symplicity. The results of the study, reported in the Lancet, demonstrated that a six month treatment with Ardian’s technology proved more effective than traditional medical treatment in patients with sustained grade 2 hypertension (baseline SBP of 160 mm Hg or more). The Symplicity System is a catheter-based low-power radiofrequency (RF) renal denervation device, thought to permanently treat hypertension by reducing or eliminating the sympathetic innervation of the renal arteries, hence “reducing both the pathologic central sympathetic drive to the kidney and the renal contribution to central sympathetic hyperactivity.”

More from the press release:

q4gwr Ardians Hypertension Treatment Outperforms Traditional Medical Treatment in Clinical Trial

The Symplicity HTN-2 trial was an international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension. One hundred-six patients were enrolled from 24 investigational sites. At baseline the randomized treatment and control patients had similar high blood pressures: 178/97 mmHg and 178/98 mmHg, respectively, despite both receiving an average daily regimen of five antihypertensive medications. After six months, the average blood pressure of the renal denervation group was reduced to 146/85 mmHg, compared to an average blood pressure of 179/98 mmHg for the control group.

The study also found that the therapy was safe, with no serious device or procedure-related events, no cardiovascular complications and no kidney-related complications.

Source : http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962039-9/abstract

Full story

FDA Grants IDE Nod to Innovative High Blood Pressure Device

FDA Grants IDE Nod to Innovative High Blood Pressure Device

FDA Grants IDE Nod to Innovative High Blood Pressure Device

BOISE– 1/18/2012 – Zona Health, developer of non-invasive, non-drug treatments for hypertension, announced that the U.S. Food and Drug Administration (FDA) conditionally approved an Investigational Device Exemption (IDE) for a pivotal clinical trial to evaluate the Company’s patented isometric handgrip therapy technology (ZonaRx™) for use in the treatment of resistant hypertension (high blood pressure in the presence of two or more medications), an especially dangerous disease affecting hundreds of millions of people worldwide. FDA approval of the IDE makes Zona Health’s study the first pivotal trial of isometric handgrip therapy for hypertension treatment.

The investigatory team for the study includes JoAnn Lindenfeld, M.D., Director of the Cardiac Transplant Program at University Hospital in Aurora, Colorado, and a member of the FDA Devices Committee; Suzanne Oparil, M.D., Professor of Medicine and Director of the Vascular Biology and Hypertension Program in the Division of Cardiovascular Disease at the University of Alabama at Birmingham, and Co-chair of The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8); and Kenneth Kronhaus, M.D., Ph.D., Cardiologist, and American Heart Association Spokesman.

“We are very pleased with the IDE approval and look forward to commencing the pivotal study to provide longer term safety and efficacy data of our ZonaRx™ hypertension treatment technology in this set of resistant hypertensive patients,” said Steven Wood, President and CEO of Zona Health. “We believe this innovative treatment has the potential to provide patients with an effective way to control their blood pressure when other treatment options are insufficient.”

The pivotal trial is a double-blind, randomized, controlled study designed to evaluate the safety and effectiveness of isometric handgrip therapy with the ZonaRx™ in patients who are taking two or more medications but cannot reach their blood pressure goals. The study will enroll approximately 200 patients in several medical centers across the U.S.

The ZonaRx™ is a medical device which enables patients to easily perform isometric handgrip therapy in the comfort of their homes. The device uses patented technology to accurately customize the therapy for each individual patient in order to trigger a specific physiological response that leads to lower blood pressure. The ZonaRx does not require a permanent implant or invasive surgery.

Clinical research shows that Zona Health’s isometric handgrip therapy may provide a significant reduction in blood pressure levels for the majority of hypertensive patients. Across several earlier studies, 135 out of 136 participants achieved significant blood pressure drops in eight weeks or less.

Hypertension is the leading attributable cause of death worldwide. It is a significant, escalating global healthcare problem affecting approximately 1.2 billion people and is associated with an increased risk of heart attack, stroke, heart failure, kidney disease and death. High blood pressure is estimated to have a direct cost to the global healthcare system of more than $500 billion annually. Although pharmaceutical therapy plays a primary role in hypertension management, drugs alone are sometimes not effective for all patients. As a result, despite lifestyle changes and the availability of modern antihypertensive agents, approximately 50 percent of patients with hypertension remain uncontrolled, and approximately 15-20 percent of those are resistant.

About Zona Health

Zona Health is a privately held medical device company headquartered in Boise, Idaho. The Company’s proprietary technology is designed for effective, non-drug and non-invasive treatment of hypertension. Zona Health currently manufactures and markets the Zona Plus™, a medical device for the improvement of overall cardiovascular health. Additional information can be found at www.zona.com.

The FDA has conditionally approved an investigational device exemption (IDE) for a pivotal clinical trial to evaluate a new patented isometric handgrip therapy technology. A product of Zona Health (Boise, ID), the ZonaRx device was developed for use in the treatment of resistant hypertension (high blood pressure that persists despite treatment by two or more medications). The IDE approval marks the first pivotal trial of isometric handgrip therapy for hypertension treatment.

Earlier clinical studies demonstrate that the isometric handgrip therapy could provide “a significant reduction in blood pressure levels for the majority of hypertensive patients,” according to Zona Health. According to earlier data, 135 out of 136 study participants achieved significant blood pressure drops in eight weeks or less.

From the announcement:

The pivotal trial is a double-blind, randomized, controlled study designed to evaluate the safety and effectiveness of isometric handgrip therapy with the ZonaRx™ in patients who are taking two or more medications but cannot reach their blood pressure goals. The study will enroll approximately 200 patients in several medical centers across the U.S.

The ZonaRx™ is a medical device which enables patients to easily perform isometric handgrip therapy in the comfort of their homes. The device uses patented technology to accurately customize the therapy for each individual patient in order to trigger a specific physiological response that leads to lower blood pressure. The ZonaRx does not require a permanent implant or invasive surgery.

Source : http://search.mywebsearch.com/mywebsearch/GGmain.jhtml?st=dns&ptb=FBA283A0-B6EF-4178-9CD1-9C01FD5858EA&n=77edc4cb&ind=2012071115&id=XPxdm045YYin&ptnrS=XPxdm045YYin&searchfor=api-public.addthis.com

Full story

Omron launches continuous Strapless Heart Rate Monitor

Omron launches continuous Strapless Heart Rate Monitor

Today Omron Healthcare, Inc., a leader in personal wellness products, launched its first-ever, continuous Strapless Heart Rate Monitor (HR-500U). Exercise enthusiasts can now take their workout to the next level comfortably without an annoying chest strap. Easy to use, the monitor is worn on the wrist and provides accurate, continuous monitoring.

“I recommend documenting your goals and tracking your progress weekly to get a better picture of your activity over time.”

“Our new Strapless Heart Rate Monitor can help you work out smarter. Our monitor alerts you when you are in the right zone to ensure an optimal workout. Walking 10,000 steps a day is recommended, but you can also achieve the same benefits walking 5,000 steps at a higher exercise level,” said Ranndy Kellogg, vice president marketing and product development at Omron. “It’s a simple solution to fit your everyday lifestyle and when you connect at our Website, your health data becomes visible, helping you achieve your goals of improved fitness and overall health.”

Strapless, Continuous Monitoring

Designed for use during a workout, the monitor measures heart rate via an optic sensor on the wrist and an accelerometer to determine pace, distance, and calories burned. As blood flow changes from beat to beat, the optic sensor measures the blood’s movement in and out of the capillaries and can determine the heart rate on a continuous basis.

Users can simply glance at the monitor on their wrist to check their heart rate without interrupting their workout. A color LCD light helps determine which zone they are in and alerts if they are in a zone too high or too low. Readings from their last workout are accessible on the monitor and 10 hours of data are stored on the unit which can be transferred to www.omronfitness.com.

Track Goals, Share Victories

By connecting the Strapless Heart Rate Monitor via USB cable at www.omronfitness.com, users can transfer data and track progress over time and share achievements via email, Facebook and Twitter with friends, family or a healthcare professional from their own personal dashboard. Mac and PC compatible, the dashboard is accessible on a personal computer or laptop and viewable on Smartphones and tablets.

“Tracking health goals such as heart rate to help improve your fitness is a key to getting results and therefore staying motivated,” said Oprah’s personal trainer Bob Greene. “I recommend documenting your goals and tracking your progress weekly to get a better picture of your activity over time.” Omron makes it easy to stay accountable with their new connected products and Website www.omronfitness.com where you can share victories and friends can keep you motivated.

Name It & Win!

It’s all in the wrist and now Omron is looking for a name for its new Strapless Heart Rate Monitor. Omron will be calling on all fans from November 15 to December 9, 2012 to help name its newest heart rate monitor. Five finalists will be announced January 8, 2013 by Bob Greene at the International Consumer Electronics Show in Las Vegas, Nev. Winners will receive Omron’s new Strapless Heart Rate monitor and a $250 gift card for fitness accessories. Entries can by submitted by visiting www.facebook.com/OmronFitness and clicking on the “It’s All in the Wrist” giveaway tab.

Source : http://www.news-medical.net/news/20121115/Omron-launches-continuous-Strapless-Heart-Rate-Monitor.aspx

Full story

Cambridge Consultants Working on a Data Router for Home Healthcare Devices

Cambridge Consultants Working on a Data Router for Home Healthcare Devices

Cambridge Consultants Working on a Data Router for Home Healthcare Devices

Mobile health device links patients and healthcare professionals anytime, anywhere

Cambridge Consultants’ Minder, powered by Vena, arms patients with a pocket-sized ‘smart’ device that can reduce recovery times and hospital visits

Cambridge Consultants, a leading technology product design and development firm, today announced a new product concept based on its low-cost Continua-compliant Vena platform. The Minder, powered by Vena, enables continuous, real-time medical data collection and transmission via cellular networks. Increasing the accuracy and frequency of patient data reporting, the Minder demonstrates a new technology solution that can lower the cost of healthcare by improving the quality of patient care. Doubling as a pocket-sized digital patient checklist, Minder is a sophisticated gateway that captures wireless medical data and transmits it to a patient’s online health record, creating higher volume and higher quality data for Electronic Medical Records (EMR). Moreover, Minder can receive real time updates to the checklist thereby enabling two way communications with healthcare professionals or caregivers, enabling more meaningful use of e-health records.

Usually, a hospital visit is required in order to record data, such as ECG or blood pressure readings, into a patient’s EMR. However, as wireless-enabled medical devices continue to grow in number, the novel Minder device showcases a viable pathway for such readings to be acquired and transmitted remotely. For physicians and hospitals, this would provide access to more accurate data to work with, while increasing efficiency and decreasing unnecessary and expensive hospital visits. For patients, the Minder takes the stress out of the often complex daily medication and monitoring regimen.

With the goal of increasing compliance via user engagement, the Minder displays an interactive timed to-do list that can be customized for individual patients. For instance, the recovering heart attack victim can now transmit their blood pressure readings from home to their EMR in real-time. If the reading is high, the Minder could instantly alert a care provider who could have the patient carry out necessary steps by sending tasks back to the Minder. If the reading is on target, it could prevent an unnecessary hospital visit.

“The rollout of ubiquitous health monitoring is gaining traction. The question is not ‘if’ but ‘which’ technologies will take hold. Between the proliferation of countless health apps for smart phones and even the first Continua Certified smart phone, we are seeing an opportunity to drive a new market and lower health care costs via connected health solutions,” said Vaishali Kamat, Group Manager, Medical Technology, Cambridge Consultants. “The other big question going forward will be: ‘How do I design a product in a smart way so that I can get it to market without regulatory hiccups?’ We believe the answer lies in standards-based technology such as Vena, which can provide reliable platforms for dedicated health devices. In the end, the companies that clear regulatory hurdles first will most likely dominate the market.”

The Vena technology used in Minder, leverages Cambridge Consultants experience with CSR’s BlueCore and Qualcomm’s Wearable Mobile Device (WMD) hardware and implements Continua Health Alliance standards for Personal Area Network (PAN) and Wide Area Network (WAN) interfaces. Devices based on Vena can receive data via Bluetooth or USB from any Continua Certified devices and transmit this data via HL7 over cellular networks, thus empowering users to manage health and wellness anytime, anywhere. The Vena wireless healthcare software stack, embeds the Bluetooth™ Health Device Profile (HDP) optimized for the secure transport of medical data and the IEEE 11073 standards for compatible exchange of information between devices. Vena has been at the heart of Cambridge Consultants’ Vena family of devices – an inhaler, the VenaHub USB gateway, and core technology for A&D Medical’s wireless blood pressure cuff and weight scale. The Qualcomm WMD supports a variety of 3G networks and provides integrated GPS, and accelerometer and Bluetooth technologies.

With the ability to customize for different target populations – whether it’s individuals with chronic diseases, seniors living independently or those trying to fight obesity — the Vena platform can support various device sizes, types, and complexities. Nevertheless, the Minder is a classic example of how a small gateway with a simple user interface can serve as a powerful and engaging tool for health management.

Cambridge Consultants has developed a new product idea, called Minder, that can link any Continua certified device with a physician or EMR system. It can also display reminder messages to take your pills from a health management system or directly from your doctor. One can imagine this device as being a central control unit for continuous glucose monitors and BP meters, while managing a drug regiment and exercise routines.

With the goal of increasing compliance via user engagement, the Minder displays an interactive timed to-do list that can be customized for individual patients. For instance, the recovering heart attack victim can now transmit their blood pressure readings from home to their EMR in real-time. If the reading is high, the Minder could instantly alert a care provider who could have the patient carry out necessary steps by sending tasks back to the Minder. If the reading is on target, it could prevent an unnecessary hospital visit.

The Vena technology used in Minder, leverages Cambridge Consultants experience with CSR’s BlueCore and Qualcomm’s Wearable Mobile Device (WMD) hardware and implements Continua Health Alliance standards for Personal Area Network (PAN) and Wide Area Network (WAN) interfaces. Devices based on Vena can receive data via Bluetooth or USB from any Continua Certified devices and transmit this data via HL7 over cellular networks, thus empowering users to manage health and wellness anytime, anywhere. The Vena wireless healthcare software stack, embeds the Bluetooth™ Health Device Profile (HDP) optimized for the secure transport of medical data and the IEEE 11073 standards for compatible exchange of information between devices.

source : http://www.cambridgeconsultants.com/news/pr/release/30/en

Full story

Computer Mouse Now Measures Your Blood Pressure

Computer Mouse Now Measures Your Blood Pressure

Computer Mouse Now Measures Your Blood Pressure

The MDMouse system is the first suite of tools being developed by CalHealth. These tools are the combination of pre-existing medical devices into conventional computer control mice, creating devices that are easier to use and more efficacious than stand-alone units.

The principal advantages incorporated into the devices will lead to an overall increase in compliance from patients, which in turn, will lead to better data collection. In addition, the process of borrowing computational power from the computer should also lead to improved results of any test or measurement taken with the device.

The first tool is designed to measure blood pressure outside of the medical environment, and to provide that information for use by the individual, clinical evaluation companies (CROs), healthcare providers and healthcare payers. It consists of an innovative mouse device which includes a blood pressure monitor and an application software package that resides on a PC where the blood pressure readings are displayed. The software application for the MDMouse system displays the blood pressure readings to the user and it also provides a means to maintain records and allow the user to access past readings at any time. In addition, the software allows the user to direct his/her records to a third party, such as a physician or insurance company, or in the event of use for clinical studies, the data can go directly to the study sponsor. Other features of the system include the ability to set alarms reminding the user to take their blood pressure or medications and set appointments with the doctor.

The MDMouse system is easy to use and readily available to the patient. In today’s world, patients are in front of their computer regularly and will have the mouse in their hands where it is convenient to take a blood pressure reading without leaving their chair. And, there is significantly greater accuracy in machine-to-machine communication, as used by the MDMouse system, than relying on patients to write down their readings and then consolidate them on a monthly basis. The blood pressure readings go directly from the MDMouse system sensor to the computer for recording on the hard drive – there is no human interaction required and none allowed. This information can be easily inserted into an Electronic Health Record (EHR) system. Once EHR systems are fully implemented in the U.S., it will be imperative that the all blood pressure monitors do what the MDMouse system already accomplishes…automatically move the data collected remotely into those EHR systems.

Inside a standard-sized computer mouse is a blood pressure finger cuff that is placed over the index finger to allow blood pressure measurement. Additional components include a pneumatic pump to inflate and deflate the cuff and a pressure sensor to identify the pulse during cuff deflation, thus allowing for measurement of blood pressure by a standard method (the “oscillometric” method). These components, and the electrical power source and processing capabilities of the computer to which the MDMouse hardware is attached, comprise a highly accurate “sphygmomanometer”. The PC, using the installed MDMouse software, along with the MDMouse device, will perform the calculations necessary to turn the digital data obtained by the sensor into useful information for display on the PC.

CalHealth anticipates having our first MDMouse product available for purchase during the first quarter of 2011.

CalHealth, an Irvine, CA company, has developed a computer mouse with a slide-out sphygmomanometer. The MDMouse is completely powered via its USB connection, and communicates with software installed on the computer to save regular readings for later analysis. Though initially it seems as a silly product idea, it may effectively increase testing compliance in people who spend a lot of time in front of the computer reading Medgadget. A company spokesman tells us that MDMouse should be coming to market sometime in the next few months.

The pressure of the cuff against the finger inserted into the cuff opening is initially increased until arterial vessel pulsation is beyond cutoff (total occlusion or shutdown of the artery). The cuff pressure is then slowly decreased until the first detection of arterial vessel pulsation occurs (the first pumping of the heart also commonly known as Korotkoff Phase I). The corresponding cuff pressure at this point will be substantially equal to systolic blood pressure which is the pressure when the heart is pumping.

As cuff pressure continues to be decreased, arterial vessel pulsations will eventually become undetectable through the cuff because of the lack of adequate cuff pressure to sense those pulsations (commonly known as Korotkoff Phase V). The pressure of the cuff at this point will be substantially equal to diastolic blood pressure – the pressure when the heart is at rest. The frequency of pulsations sensed between the systolic and diastolic pressures is measured and is substantially equal to the heartbeat rate or pulse rate of the individual. These two cuff pressures and the pulsation frequency are measured and captured by the MDMouse application software.

The application software installed on the user’s PC then utilizes the digital data to create a display of the individual’s blood pressure readings and pulse rate. The software also provides additional functions including recording the data and graphically plotting data over a number of parameters such as three day averages. Communication of the data is also handled by the application software, including sending emails to medical personnel or archiving data.

Source : http://www.mdmouse.com/957.html

Full story

Home monitoring may not improve blood pressure control in patients with hypertension and stroke

Home monitoring may not improve blood pressure control in patients with hypertension and stroke

Home blood pressure monitoring may help patients with hypertension and stroke but did not improve blood pressure control for patients who had normal blood pressure at the start or those with disabilities, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).

“Overall, home monitoring did not improve blood pressure control in an unselected group of patients with hypertension and a history of stroke. However, it was associated with more changes in antihypertensive treatment during the trial, which suggested more active management in the intervention group,” writes Sally Kerry, Centre for Primary Care and Public Health, Queen Mary, University of London, UK, with coauthors.

Good blood pressure control can significantly reduce the risk of recurrent stroke in the estimated 15 million people who have strokes each year worldwide. Studies show that home monitoring is associated with lower blood pressure.

The study involved 381 participants aged 30 (mean 72) years from three stroke units in London, UK, who were assigned to home monitoring or to a control group of usual care. Participants in the monitoring group were given a blood pressure monitor, brief training and telephone support from a nurse. The trial, including follow up, was conducted from March 2007 to August 2009. A total of 23% of participants were from ethnic minorities, and 45% had some disability due to stroke, including many frail, elderly patients. The study included patients with a range of blood pressure levels, rather than a group with poorly controlled levels.

“Home monitoring depended on patients taking their blood pressure, recognizing if readings were consistently over target, understanding the need for intensification of treatment, visiting their physician for review and appropriate management by their physician,” write the authors.

After 12 months, most patients were still monitoring, although patients with disabilities and whose care givers did not live with them had difficulties with monitoring.

“Overall, home monitoring did not improve blood pressure control in patients with hypertension and a history of stroke. It was associated with a fall in systolic pressure in patients who had uncontrolled blood pressure at baseline and those without disability due to stroke,” conclude the authors.

Source : http://www.news-medical.net/news/20121106/Home-monitoring-may-not-improve-blood-pressure-control-in-patients-with-hypertension-and-stroke.aspx

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 3123
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes